C12Y 207/01107
Diacylglycerol kinase
Official title: Diacylglycerol kinase (2.7.1.107)
C12Y207/01107 (Diacylglycerol kinase) appears on 5 US grants and 14 published applications in this corpus.
Search patents in C12Y- Granted patents
- 5
- Published applications
- 14
- Assignees
- 11
- Inventors
- 32
- Latest grant
- 15 Apr 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 0 | 3 |
| 2020 | 1 | 0 |
| 2021 | 0 | 2 |
| 2022 | 0 | 1 |
| 2023 | 1 | 2 |
| 2024 | 1 | 3 |
| 2025 | 1 | 0 |
By publication year.
Recent patents
- Artificially manipulated immune cell15 Apr 2025US 12,275,963 B2Toolgen Incorporated
- Inhibition of diacylglycerol kinase to augment adoptive T cell transfer19 Mar 2024US 11,931,380 B2The Trustees of the University of Pennsylvania
- Recombinant Dgkk gene for fragile X syndrome gene therapy7 Mar 2023US 11,597,936 B2Centre National De La Recherche Scientifique
- Composition comprising neoagarooligosaccharide as active ingredient, for prevention or treatment of sepsis or septic shock4 Feb 2020US 10,548,916 B2Dynebio Inc.
- Inhibition of diacylglycerol kinase to augment adoptive T cell transfer10 Apr 2018US 9,937,205 B2The Trustees of the University of Pennsylvania
- Inhibition of Diacylglycerol Kinase to Augment Adoptive T cell Transfer19 Sep 2024US 2024/0307445 A1The Trustees of the University of Pennsylvania
- Methods and compositions for generating stem cell-derived immune cells with enhanced function11 Apr 2024US 2024/0117311 A1
- Engineered bacteria and methods of producing triacylglycerides11 Apr 2024US 2024/0117392 A1President and Fellows of Harvard College
- Chimeric antigen receptor-expressing immunocompetent cells17 Aug 2023US 2023/0257705 A1Kyoto University
- Recombinant dgkk gene for fragile x syndrome gene therapy10 Aug 2023US 2023/0250404 A1Centre National De La Recherche Scientifique
Most cited
By later US patents